It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autophagy inducers can prevent cardiovascular aging and age-associated diseases including atherosclerosis. Therefore, we hypothesized that autophagy-inducing compounds that act on atherosclerosis-relevant cells might have a protective role in the development of atherosclerosis. Here we identified 3,4-dimethoxychalcone (3,4-DC) as an inducer of autophagy in several cell lines from endothelial, myocardial and myeloid/macrophagic origin, as demonstrated by the aggregation of the autophagosome marker GFP-LC3 in the cytoplasm of cells, as well as the downregulation of its nuclear pool indicative of autophagic flux. In this respect, 3,4-DC showed a broader autophagy-inducing activity than another chalcone (4,4- dimethoxychalcone), spermidine and triethylene tetramine. Thus, we characterized the potential antiatherogenic activity of 3,4-DC in two different mouse models, namely, (i) neointima formation with smooth muscle expansion of vein segments grafted to the carotid artery and (ii) genetically predisposed ApoE−/− mice fed an atherogenic diet. In the vein graft model, local application of 3,4-DC was able to maintain the lumen of vessels and to reduce neointima lesions. In the diet-induced model, intraperitoneal injections of 3,4-DC significantly reduced the number of atherosclerotic lesions in the aorta. In conclusion, 3,4-DC stands out as an autophagy inducer with potent antiatherogenic activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Gustave Roussy Comprehensive Cancer Institute, Metabolomics and Cell Biology Platforms, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); Centre de Recherche des Cordeliers, INSERM U1138, Equipe 11 labellisée Ligue contre le Cancer, Paris, France (GRID:grid.417925.c) (ISNI:0000 0004 0620 5824)
2 Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM) and Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (GRID:grid.466793.9) (ISNI:0000 0004 1803 1972)
3 Central South University, The Center of Clinical Pharmacology, The Third Xiangya Hospital, Changsha, China (GRID:grid.216417.7) (ISNI:0000 0001 0379 7164)
4 Gustave Roussy Comprehensive Cancer Institute, Metabolomics and Cell Biology Platforms, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); Centre de Recherche des Cordeliers, INSERM U1138, Equipe 11 labellisée Ligue contre le Cancer, Paris, France (GRID:grid.417925.c) (ISNI:0000 0004 0620 5824); Nankai University, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, Tianjin Key Laboratory of Protein Science, Haihe Laboratory of Cell Ecosystem, College of Life Sciences, Tianjin, China (GRID:grid.216938.7) (ISNI:0000 0000 9878 7032)
5 Gustave Roussy Comprehensive Cancer Institute, Metabolomics and Cell Biology Platforms, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); Centre de Recherche des Cordeliers, INSERM U1138, Equipe 11 labellisée Ligue contre le Cancer, Paris, France (GRID:grid.417925.c) (ISNI:0000 0004 0620 5824); Hôpital Européen Georges Pompidou, AP-HP, Institut du Cancer Paris CARPEM, Department of Biology, Paris, France (GRID:grid.414093.b) (ISNI:0000 0001 2183 5849)